Li et al., “Effect of a . . . ,” Eur. J. Pharm. Biopharm., 39:216-221, 1993. |
Byron et al., “Drug Delivery via the Respiratory . . . ,” Journal of Aerosol Medicine, 7:49-75, 1994. |
Nagano et al., “New Method of Insulin . . . ,” Jikeikai Med. J., 32:503-506, 1985. |
Elliott et al., “Parenteral absorption of insulin . . . ,” Aust. Paediatr. J., 23:293-297, 1987. |
Sakr., “A new approach for insulin . . . ,” International Journal of Pharmaceutics, 86:1-7, 1992. |
Liu et al., “Pulmonary Delivery of Free . . . ,” Pharmaceutical Research, 10:228-232, 1993. |
Jaegfeldt et al., “Particle size distribution from different modifications . . . ,” Proceedings of an international workshop on a new inhaler, May 21-22, 1987, London, U.K., pp. 90-99. |
Li et al., “Effect of a Conjugated Bile Salt on the Pulmonary . . . ,” Eur. J. Pharm. Biopharm, vol. 39, pp. 216-221, 1993. |
Okumura et al., “Intratracheal delivery of insulin Absorption . . . ,” International Journal of Pharmaceutics, vol. 88, pp. 63-73, 1992. |
Wetterlin, “Turbuhaler: A New Powder Inhaler for Administration . . . ,” Pharmaceutical Research, vol. 5, pp. 506-508, 1988. |
Yamamoto et al., “Absorption Enhancement of Intrapulmonary Administered Insulin . . . ,” J. Pharm. Pharmacol, vol. 46, pp. 14-18, 1994. |
“Bioavailability of pulmonary delivered peptides and proteins: alpha-interferon, calcitonins and parathyroid hormones”, J. Control. Release (Netherlands), (1994), 28/1-3, pp. 79-85. |
Almer et al., Diabetes Res. and Clin. Pract, 5:S163 (1988). |
Bjork, Acta Univ. Uppsala, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, 103 (1993). |
Laube et al., “Preliminary Study of the Efficacy of Insulin Aerosol Delivered by Oral Inhalation in Diabetic Patients”, JAMA, 269(16):2106-2109 (1993). |
Lee et al., “Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to-Protein Ratio”, J. Pharm. Sci., 80(8):725-729, (1991). |
Lee et al., “Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption”, Critical Rev. Therapeut. Drug Carrier Systems, 8(2):91-192 (1991). |
Komada et al., “Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung”, J. Pharm. Sciences, 83(6):863-867 (1994). |
Ruin, Sydsvenska (Dagbladet), Monday, Jun. 12, 1989, Diabetics May Not Need their Insulin Shots. |
Schipper et al., “Nasal Insulin Delivery with Dimethyl-β-Cyclodextrin as an Absorpotion Enhancer in Rabbits: Powder More Effective than Liquid Formulations”, Pharm. Res., 10(5):682-686 (1993). |
Timisina et al., “Drug delivery to the respiratory tract using dry powder inhalers”, International Journal of Pharmaceutics, 101:1-13 (1994). |
Wearley, “Recent Progress in Protein and Peptide Delivery by Noninvasive Routes”, Crit. Rev. Therapeutic Drug Carrier Systems, 8(4):331-394 (1991). |
Gordon et al., Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts; Proc. Natl. Acad. Sci. 82:7419-7423, 1985. |
Zinman, The Physiologic Replacement of Insulin, The New England Journal of Medicine 321/6:363-370, 1989. |
Olanoff et al., Method to Enhance Intranasal Peptide Delivery, Controlled-Release Technology Pharmaceutical Applications, Lee et al., Ed. Published 1987 by the American Chemical Society, pp. 301-309. |
Mishima et al., Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats, J. Pharm. Sci. 10:624-631, 1987. |